Pharmaceutical Nanotechnology and Nanomedicine

Biography

Biography: Surendra Adusumalli

Abstract

In recent years, researchers and medication designers have been paying a significant amount of attention to novel nanotechnology techniques to improve drug delivery to the central nervous system (CNS). The treatment of neurological conditions, including Alzheimer's disease, Parkinson's disease, brain tumours, and stroke, may be significantly impacted by nanotechnology in the not-too-distant future. Several studies have shown that nanomaterials have been effectively employed for the treatment of illnesses of the central nervous system (CNS), including neurodegeneration. In this context, nanocarriers have been essential in facilitating the targeted administration of chemotherapeutics, which has resulted in the effective prevention of disease development in malignant brain tumours. Therefore, the most effective use of nanomaterials is the use of these compounds in the treatment of CNS disorder, as this application improves the overall impact of the medicine and underlines the significance of nano-therapeutics. Treatments for CNS illnesses have advanced in recent decades, yet many patients have few alternatives. Nanotechnology is a promising new strategy to treat neurological disorders that might revolutionize CNS-targeted therapies. Nanoengineered molecules may traverse the blood–brain barrier, target particular cells or signaling systems, react to endogenous cues, or function as a matrix to enhance axon elongation and cell survival. The great diversity of available nanotechnologies permits the selection of a nanoscale material best matched to a CNS disorder's treatment problems. The purpose of this research was to review the evidence on the uses of nanotechnology in the creation of drug delivery systems that have the capability of passing through the blood-brain barrier (BBB) to transport therapeutic drugs to the central nervous system (CNS)